BIIB vs LH: fair value comparison
Biogen Inc. and Labcorp Holdings Inc. · Updated 2026-10-19
BIIB currently screens as overvalued while LH screens as fairly valued. Within Healthcare, LH currently sits closer to the top of our ranking by discount to fair value. BIIB carries the stronger quality grade.
| BIIB | LH | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $225.71 | $312.15 |
| 12-month range | $147.86–$235.35 | $246.64–$339.34 |
| Rank by discount to fair value | #73 of 108 Healthcare | #69 of 108 Healthcare |
| Quality grade | B | D |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BIIB fair value analysis · LH fair value analysis